Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2010-04-23
2011-11-29
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S616000
Reexamination Certificate
active
08067472
ABSTRACT:
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6469058 (2002-10-01), Grove et al.
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 6960685 (2005-11-01), Watkins
patent: 7148257 (2006-12-01), Bacopoulos et al.
patent: 7375137 (2008-05-01), Bacopoulos et al.
patent: 7399787 (2008-07-01), Chiao et al.
patent: 7732490 (2010-06-01), Richon et al.
patent: 7851509 (2010-12-01), Miller et al.
patent: 2002/0183388 (2002-12-01), Gudas et al.
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammer et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0002506 (2004-01-01), Breslow et al.
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2004/0266818 (2004-12-01), Breslow et al.
patent: 2005/0004007 (2005-01-01), Grant et al.
patent: 2006/0079551 (2006-04-01), Richon et al.
patent: 2006/0167103 (2006-07-01), Bacopoulos et al.
patent: 2006/0276547 (2006-12-01), Bacopoulos et al.
patent: 2007/0060614 (2007-03-01), Bacopoulos et al.
patent: 2007/0117815 (2007-05-01), Pluda et al.
patent: 2007/0190022 (2007-08-01), Bacopoulos et al.
patent: 2007/0197473 (2007-08-01), Frankel et al.
patent: 2008/0194692 (2008-08-01), Miller et al.
patent: 2008/0221138 (2008-09-01), Bunn et al.
patent: 2008/0227862 (2008-09-01), Richon et al.
patent: 2008/0228005 (2008-09-01), Miller
patent: 2008/0249179 (2008-10-01), Bacopoulos et al.
patent: 2009/0012175 (2009-01-01), Bacopoulos et al.
patent: 2009/0042992 (2009-02-01), Miller et al.
patent: 2009/0054720 (2009-02-01), Sgouros et al.
patent: 2009/0227674 (2009-09-01), Richon et al.
patent: 2010/0168242 (2010-07-01), Miller et al.
patent: 0547000 (1993-06-01), None
patent: 10262694 (1998-10-01), None
patent: WO-9531977 (1995-11-01), None
patent: WO-9839965 (1998-09-01), None
patent: WO-9840080 (1998-09-01), None
patent: WO-9855449 (1998-12-01), None
patent: WO-9938525 (1999-08-01), None
patent: WO-0021979 (2000-04-01), None
patent: WO-0071703 (2000-11-01), None
patent: WO-0116106 (2001-03-01), None
patent: WO-0118171 (2001-03-01), None
patent: WO-0129199 (2001-04-01), None
patent: WO-0138322 (2001-05-01), None
patent: WO-0170675 (2001-09-01), None
patent: WO-0215921 (2002-02-01), None
patent: WO-0222577 (2002-03-01), None
patent: WO-0230879 (2002-04-01), None
patent: WO-0246144 (2002-06-01), None
patent: WO-02055017 (2002-07-01), None
patent: WO-02085400 (2002-10-01), None
patent: WO-03013493 (2003-02-01), None
patent: WO-03075839 (2003-09-01), None
patent: WO-2007022408 (2007-02-01), None
patent: WO-2007056162 (2007-05-01), None
O'Connor et al. Blood, Nov. 16, 2001, vol. 98, No. 11, Part 1, p. 611a (Abstract attached).
Richon et al., “Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of Cancers”,Blood Cells, Molecules, and Diseases, 27(1):260-264 (2001).
“Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA”, Oct. 30, 2002.
“Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias”, Jul. 1, 2003.
“Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development”, Sep. 20, 2002.
“Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO”, Jun. 2, 2003.
“Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium”, Nov. 21, 2002.
“Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial”, Oct. 13, 2003.
“Aton Pharma, Inc. Reports on Phase I Trial of SAHA”, Aug. 14, 2002.
Adams and Elliott,Oncogene, 19:6687-6692 (2000).
Adhikari et al., “Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate”,Proceedings of the American Association for Cancer Research Annual Meeting, 39:312 (1998).
Alexandrov et al., “Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations”,FEBS Letters, 434:209-214 (1998).
Almenara et al., “Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)”,Leukemia, 16:1331-1343 (2002).
Amin et al., “Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyelocytic Leukemia (15:17)”,British Journal of Haematology, 115:287-297 (2001).
Andrews et al.,Intl. J. Parasitol., 30:761-768 (2000).
Archer et al.,Proc. Natl. Acad. Sci. USA, 95:6791-6796 (1998).
Aron et al., “Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent with Activation of Caspase 8-Mediated Apoptosis and Down-Regulation of c-FLIP Protein”,Blood, 102(2):652-658 (2003).
Bates et al.,Proc. American Society of Clinical Oncology18:180a, Abstract No. 693 (1999).
Benoit et al., “Increased Inhibition of Proliferation of Human B Cell Lymphomas Following Litigation of CD40, and either CD19, CD20, CD95 or Surface Immunoglobulin”,Immunopharmacology, (35):129-139 (1996).
Bhalla et al., “Co-treatment with the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells”,American Society of Hematology, 44thMeeting of the American Society of Hematology, Abstract 4611 (2002).
Bode et al., “Links Between Effects of Butyrate on Histone Hyperacetylation and Regulation of interferon Synthesis in Namalva and FS-4 Cell Lines”,Journal of Interferon Research, 2(2):159-166 (1982).
Bruner et al.,Blood(2002), 44thAnnual Meeting of the American Society of Hematology, vol. 100, No. 11, pp. Abstract No. 1492, “Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Fludarabine Refractory Chronic Lymphocytic Leukemia”.
Buckley et al., “Alterations in pim-1 and c-myc Expression Associated with Sodium Butyrate-induced G
Chiao Judy H.
Kelly William Kevin
Miller Thomas A.
Richon Victoria M.
Anderson James
Elrifi, Esq. Ivor R.
Merck HDAC Research, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Sloan-Kettering Institute for Cancer Research
LandOfFree
Methods of treating Hodgkin's and non-Hodgkin's lymphoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating Hodgkin's and non-Hodgkin's lymphoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating Hodgkin's and non-Hodgkin's lymphoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255162